ArticleCancers2022

Determinants of Survival and Post-Progression Outcomes by Sorafenib-Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma.

I-Cheng Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.